JP2016199549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016199549A5 JP2016199549A5 JP2016095779A JP2016095779A JP2016199549A5 JP 2016199549 A5 JP2016199549 A5 JP 2016199549A5 JP 2016095779 A JP2016095779 A JP 2016095779A JP 2016095779 A JP2016095779 A JP 2016095779A JP 2016199549 A5 JP2016199549 A5 JP 2016199549A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100033625 Killer cell immunoglobulin-like receptor 2DS3 Human genes 0.000 claims description 133
- 108010077854 Natural Killer Cell Receptors Proteins 0.000 claims description 133
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 90
- 239000012634 fragment Substances 0.000 claims description 88
- 150000001875 compounds Chemical class 0.000 claims description 78
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 44
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 44
- 208000014951 hematologic disease Diseases 0.000 claims description 33
- 230000003211 malignant effect Effects 0.000 claims description 33
- 208000019838 Blood disease Diseases 0.000 claims description 32
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 31
- 230000003902 lesion Effects 0.000 claims description 30
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 claims description 29
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 claims description 29
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 27
- 230000002159 abnormal effect Effects 0.000 claims description 23
- 210000001185 bone marrow Anatomy 0.000 claims description 21
- 101710085938 Matrix protein Proteins 0.000 claims description 20
- 101710127721 Membrane protein Proteins 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 201000009295 smoldering myeloma Diseases 0.000 claims description 18
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 claims description 17
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 17
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 16
- 210000004180 plasmocyte Anatomy 0.000 claims description 16
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 claims description 14
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 claims description 14
- 210000000822 natural killer cell Anatomy 0.000 claims description 14
- 208000032839 leukemia Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 208000034578 Multiple myelomas Diseases 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 9
- 208000031404 Chromosome Aberrations Diseases 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 239000002955 immunomodulating agent Substances 0.000 claims description 8
- 230000002584 immunomodulator Effects 0.000 claims description 8
- 229940121354 immunomodulator Drugs 0.000 claims description 8
- 230000002068 genetic effect Effects 0.000 claims description 7
- 230000008707 rearrangement Effects 0.000 claims description 7
- 108010043610 KIR Receptors Proteins 0.000 claims description 6
- 102000002698 KIR Receptors Human genes 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 206010067477 Cytogenetic abnormality Diseases 0.000 claims description 5
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108010069149 HLA-C*04 antigen Proteins 0.000 claims description 4
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 102100029382 CMRF35-like molecule 6 Human genes 0.000 claims description 3
- 101000990034 Homo sapiens CMRF35-like molecule 6 Proteins 0.000 claims description 3
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 claims description 3
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 3
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims description 3
- 108700042075 T-Cell Receptor Genes Proteins 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 239000013059 antihormonal agent Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 230000013595 glycosylation Effects 0.000 claims description 3
- 238000006206 glycosylation reaction Methods 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 238000010837 poor prognosis Methods 0.000 claims description 3
- 230000017854 proteolysis Effects 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 8
- 230000005856 abnormality Effects 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 238000011443 conventional therapy Methods 0.000 claims 2
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101150010487 are gene Proteins 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 131
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 74
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 74
- 239000000203 mixture Substances 0.000 description 21
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41597310P | 2010-11-22 | 2010-11-22 | |
| US61/415,973 | 2010-11-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541022A Division JP6224457B2 (ja) | 2010-11-22 | 2011-11-22 | Ｎｋ細胞調節治療及び悪性血液疾患の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016199549A JP2016199549A (ja) | 2016-12-01 |
| JP2016199549A5 true JP2016199549A5 (OSRAM) | 2017-03-09 |
Family
ID=46146390
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541022A Expired - Fee Related JP6224457B2 (ja) | 2010-11-22 | 2011-11-22 | Ｎｋ細胞調節治療及び悪性血液疾患の治療方法 |
| JP2016095779A Pending JP2016199549A (ja) | 2010-11-22 | 2016-05-12 | Ｎｋ細胞調節治療及び悪性血液疾患の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541022A Expired - Fee Related JP6224457B2 (ja) | 2010-11-22 | 2011-11-22 | Ｎｋ細胞調節治療及び悪性血液疾患の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9844593B2 (OSRAM) |
| EP (1) | EP2643350A4 (OSRAM) |
| JP (2) | JP6224457B2 (OSRAM) |
| CN (2) | CN106963947A (OSRAM) |
| AR (1) | AR083957A1 (OSRAM) |
| BR (1) | BR112013012138B1 (OSRAM) |
| CA (1) | CA2818684C (OSRAM) |
| EA (1) | EA035033B1 (OSRAM) |
| MX (1) | MX355483B (OSRAM) |
| TW (1) | TWI664191B (OSRAM) |
| WO (1) | WO2012071411A2 (OSRAM) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090191213A9 (en) * | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| US20090196850A1 (en) * | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| US9067997B2 (en) * | 2011-05-25 | 2015-06-30 | Innate Pharma Sa | Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders |
| EP2893003B1 (en) * | 2012-09-04 | 2021-03-31 | Inven2 AS | Selective and controlled expansion of educated nk cells |
| AU2013327116C1 (en) | 2012-10-02 | 2018-08-30 | Bristol-Myers Squibb Company | Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer |
| CN107880126B (zh) | 2012-12-21 | 2021-03-30 | 西雅图基因公司 | 抗ntb-a抗体及相关组合物和方法 |
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| BR112015027567B1 (pt) | 2013-05-03 | 2024-02-20 | Ohio State Innovation Foundation | Polipeptídeo, sequência de ácido nucleico isolada, vetor, método de obtenção de célula, uso de uma célula |
| WO2015069785A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
| WO2015195555A1 (en) * | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| AU2016219785B2 (en) | 2015-02-20 | 2021-10-28 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
| RU2571551C1 (ru) * | 2015-04-16 | 2015-12-20 | Закрытое акционерное общество "ПЕПТЕК" | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором |
| NZ735820A (en) | 2015-04-17 | 2025-02-28 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| DE112016002056T5 (de) | 2015-05-06 | 2018-02-08 | Snipr Technologies Limited | Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen |
| CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| US10736963B2 (en) | 2015-07-24 | 2020-08-11 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| CN108884159A (zh) | 2015-11-07 | 2018-11-23 | 茂体外尔公司 | 用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物 |
| HRP20240617T1 (hr) | 2016-05-20 | 2024-07-19 | Biohaven Therapeutics Ltd. | Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| KR101926166B1 (ko) * | 2016-05-24 | 2018-12-06 | 재단법인 아산사회복지재단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| EP3518946A4 (en) | 2016-09-27 | 2020-09-09 | Board of Regents, The University of Texas System | METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME |
| JP7041136B2 (ja) | 2016-10-12 | 2022-03-23 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｔｕｓｃ２免疫療法のための方法および組成物 |
| EP3551226A1 (en) | 2016-12-12 | 2019-10-16 | MultiVir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| EP3579879A4 (en) | 2017-02-09 | 2020-12-16 | Memorial Sloan Kettering Cancer Center | ANTI-BODY ANTI-KIR3DL1 |
| EP3601537A4 (en) | 2017-03-27 | 2021-01-13 | National University of Singapore | STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS |
| SG11201908492PA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| KR20250036268A (ko) | 2017-03-31 | 2025-03-13 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| UA129446C2 (uk) | 2017-10-13 | 2025-04-30 | Гарпун Терап'Ютікс, Інк. | Триспецифічні білки і способи їх застосування |
| JP2020536894A (ja) | 2017-10-15 | 2020-12-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 腫瘍処置法 |
| CN111801348A (zh) | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| EP4066851A1 (en) | 2018-03-25 | 2022-10-05 | SNIPR Biome ApS. | Treating & preventing microbial infections |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| KR20200139724A (ko) | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| KR20200138741A (ko) | 2018-04-02 | 2020-12-10 | 내셔널 유니버시티 오브 싱가포르 | 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화 |
| WO2019195769A1 (en) * | 2018-04-06 | 2019-10-10 | The Brigham And Women's Hospital, Inc. | Methods of diagnosing and treating aggressive cutaneous t-cell lymphomas |
| CN108728527B (zh) * | 2018-06-06 | 2020-06-09 | 青岛泱深生物医药有限公司 | Hcst基因作为诊治子痫前期的靶标 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| CN113166762B (zh) | 2018-12-21 | 2025-01-14 | 瓦莱里奥治疗公司 | 新的偶联核酸分子及其用途 |
| KR102210455B1 (ko) * | 2019-02-28 | 2021-02-02 | 사회복지법인 삼성생명공익재단 | 자연살해세포 활성 검출용 미세입자 및 이를 이용한 검출 방법 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| CN111973739B (zh) * | 2019-05-23 | 2024-02-13 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| JP2022534982A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| CN114222761B (zh) * | 2020-07-14 | 2024-02-20 | 浙江道尔生物科技有限公司 | 一种抗cld18a2的单域抗体 |
| EP4204453A1 (en) | 2020-08-31 | 2023-07-05 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022108877A1 (en) * | 2020-11-18 | 2022-05-27 | The Regents Of The University Of California | Depleting monoclonal antibodies against natural killer cells |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| RS66849B1 (sr) | 2020-12-28 | 2025-06-30 | Bristol Myers Squibb Co | Kompozicije antitela i postupci njihove upotrebe |
| US20220233689A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Methods of treating tumors |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| KR20240038769A (ko) * | 2021-07-28 | 2024-03-25 | 머크 샤프 앤드 돔 엘엘씨 | 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| IL313439A (en) | 2021-12-16 | 2024-08-01 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
| KR20240159621A (ko) | 2022-03-18 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | 폴리펩티드를 단리하는 방법 |
| AU2023281061A1 (en) | 2022-06-02 | 2024-12-05 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| AU2023393653A1 (en) | 2022-12-14 | 2025-05-22 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| EP1556033A4 (en) * | 2002-05-17 | 2006-05-31 | Celgene Corp | METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| KR20060079180A (ko) | 2003-07-02 | 2006-07-05 | 노보 노르디스크 에이/에스 | Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법 |
| CN1852924A (zh) * | 2003-07-02 | 2006-10-25 | 依奈特制药公司 | Pan－kir2dl nk－受体的抗体及其在诊断及治疗中的应用 |
| PT1648507T (pt) * | 2003-07-24 | 2017-03-20 | Innate Pharma Sa | Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk |
| DK2287195T3 (da) | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
| US20090196850A1 (en) * | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| PL1836225T3 (pl) * | 2005-01-06 | 2012-05-31 | Novo Nordisk As | Czynniki wiążące kir i sposoby ich stosowania |
| CA2675291C (en) * | 2007-01-11 | 2017-05-23 | Novo Nordisk A/S | Killer ig-like receptor (kir) antibodies, formulations, and uses thereof |
| US20100099084A1 (en) | 2008-10-17 | 2010-04-22 | Maher Albitar | Detection of npm1 nucleic acid in acellular body fluids |
-
2011
- 2011-11-22 US US13/988,954 patent/US9844593B2/en active Active
- 2011-11-22 WO PCT/US2011/061840 patent/WO2012071411A2/en not_active Ceased
- 2011-11-22 CN CN201710194545.4A patent/CN106963947A/zh active Pending
- 2011-11-22 AR ARP110104349A patent/AR083957A1/es unknown
- 2011-11-22 MX MX2013005673A patent/MX355483B/es active IP Right Grant
- 2011-11-22 CA CA2818684A patent/CA2818684C/en active Active
- 2011-11-22 EA EA201390756A patent/EA035033B1/ru not_active IP Right Cessation
- 2011-11-22 CN CN2011800622682A patent/CN103298831A/zh active Pending
- 2011-11-22 TW TW100142827A patent/TWI664191B/zh active
- 2011-11-22 EP EP11843281.4A patent/EP2643350A4/en not_active Ceased
- 2011-11-22 BR BR112013012138-6A patent/BR112013012138B1/pt not_active IP Right Cessation
- 2011-11-22 JP JP2013541022A patent/JP6224457B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-12 JP JP2016095779A patent/JP2016199549A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016199549A5 (OSRAM) | ||
| JP2014501729A5 (OSRAM) | ||
| US20220332816A1 (en) | Anti-tigit antibodies | |
| EP3621694B1 (en) | Lrrc33 inhibitors and use thereof | |
| JP2018502892A (ja) | ガイドとして自身のカルレティキュリンを使用して癌細胞を食べるマクロファージ | |
| JP2016039824A (ja) | 生物学的材料およびそれらの使用法 | |
| US10066014B2 (en) | Anti CD84 antibodies, compositions comprising same and uses thereof | |
| BR112013032217B1 (pt) | uso de um anticorpo anti-nkg2a | |
| KR20190038919A (ko) | 항-nkg2d 항체로 크론병을 치료하는 방법 | |
| US20230348611A1 (en) | Obinutuzumab treatment of a dlbcl patient subgroup | |
| TW202133877A (zh) | 全身性紅斑狼瘡中之ｉ型干擾素抑制 | |
| US11136383B2 (en) | Methods and compositions for modulaton of transforming growth factor beta-regulated functions | |
| US20230279105A1 (en) | Anti-tim-3 antibodies | |
| US12116415B2 (en) | Anti-BCMA antibodies | |
| US12415851B2 (en) | Monoclonal antibodies to ELTD1 and uses thereof | |
| CN105492023A (zh) | Tspan 33是用于治疗b细胞霍奇金淋巴瘤的抗体靶向疗法的候选物 | |
| Moszczuk et al. | The Role of Glomerular and Serum Expression of Lymphocyte Activating Factors BAFF and APRIL in Patient with Membranous and IgA Nephropathies | |
| JP2023523450A (ja) | 非小細胞肺がん免疫療法のための方法及び組成物 | |
| US20250320294A1 (en) | Bispecific antibody for t-cell modulation | |
| CA3048198A1 (en) | Methods of treating multiple myeloma | |
| HK40103766A (en) | Lrrc33 inhibitors and use thereof | |
| CN117355330A (zh) | 抗cd19组合疗法 | |
| WO2025085512A9 (en) | Combination therapies with ulbp2 targeting antibodies for treating cancers | |
| Vidal Crespo | Targeting the crosstalk between tumor cells and microenvironment: a new therapeutic approach for the treatment of lymphoid neoplasms |